
LOW INCIDENCE OF BCR-ABL TRANSCRIPTS IN
ESSENTIAL THROMBOCYTHEMIA
Panovska I, Pavkovic M, Cevreska L, Efremov DG* *Corresponding Author: Dimitar G. Efremov, M.D., Ph.D., Associate Professor of Medicine, Department of Hematology, Faculty of Medicine, Vodnjanska 17, 1000 Skopje, Republic of Macedonia; Tel: +389-2-147775; Fax: +389-2-110548; E-mail: defremov@mt.net.mk
page: 17
|
MATERIALS AND METHODS
We investigated 56 consecutive patients with ET (24 males and 32 females; median age 47 years; age range 33 to 69) who presented at our Department during the last 4 years. Routine laboratory investigations, peripheral blood smears, leukocyte alkaline phosphatase (LAP) score and bone marrow examination were carried out in all cases. All patients fulfilled the criteria for diagnosis of ET defined by the PVSG [3].
The detection of the two subtypes of BCR-ABL transcripts, b2/a2 and b3/a2, was performed by reverse transcriptase-polymerase chain reaction (RT-PCR) on total RNA extracted from bone marrow and peripheral blood samples. Total cellular RNA was extracted by the method of Chomczynski and Sacchi [15]. Complementary DNA (cDNA) was synthesized using random hexamers and the GeneAmp RNA/PCR kit (Perkin Elmer Cetus, Norwalk, CT, USA), following the recommendations of the manufacturer. The following primers were used: consensus ABL 3 (5’-CCG CTG CTC AGC AGA TAC TC-3’), BCR 1 (5’-TGC AGA GTG GAG GGA GAA CAT-3’) and ABL 4 (5’-CTT CTC GCT GGA CCC AGT GA-3’). PCR was performed in a DNA Thermal cycler 2400 (Perkin Elmer Cetus) under the following conditions: 1 min. at 95°C, 1 min. at 65°C, 90 seconds at 72°C, for a total of 45 cycles. The PCR products were visualized after electrophoresis on 2% agarose gels with ethidium bromide and UV illumination. The size of the obtained fragments was 496 and 571 bp, respectively, for the b2/a2 and b3/a2 transcript, and 260 bp for the control ABL product.
|
|
|
|



 |
Number 27 VOL. 27 (2), 2024 |
Number 27 VOL. 27 (1), 2024 |
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|